The document discusses treatment options for chlamydia-induced reactive arthritis, highlighting a case study where the TNF-alpha inhibitor etanercept successfully alleviated symptoms in a patient unresponsive to standard treatments. It emphasizes the complex nature of the disease, including the persistence of C. trachomatis in synovial tissues even during remission and the importance of inflammation management. Future research directions include understanding bacterial replication mechanisms and the impact of targeting specific inflammatory proteins in chronic cases.
This slide introduces the topic, focusing on Chlamydia-induced Reactive Arthritis and its treatment.
Provides an outline of the presentation covering research approach, case reports, treatment plans, and future research questions.
Discusses the methodology used in the research, emphasizing systematic review and the approach to data collection.
Details the P.I.C.O. approach for establishing research parameters including patient problems, interventions, and outcomes.
Defines Reactive Arthritis and its association with Chlamydia trachomatis, including prevalence statistics, and related conditions.Outlines the significance of Chlamydia trachomatis as a leading STI and its impact on reactive arthritis cases.
Overview of historical treatments for Reactive Arthritis, leading to discussions on modern therapies.
Describes a case study of a patient with Reiter’s Syndrome and successful treatment using Etanercept.
Concludes that Etanercept may improve symptoms in non-responding patients, emphasizing its dual role in inflammation.
Discusses the effectiveness of combination therapy using Etanercept and methotrexate in achieving remission.
Defines remission in Reactive Arthritis cases and outlines the potential for chronic progression.
Presents systematic study findings on C. trachomatis during the remission phase and bacterial load comparisons.
Reports on investigations regarding gene expression patterns in patients with reactive arthritis and remission.
Concludes that low bacterial loads exist during remission while inflammatory markers remain significant.
Identifies gaps in understanding Chlamydia replication and the impacts of immunosuppressive treatments.
Acknowledges contributions from Dr. F.M., M.D. to the presentation.
Lists scholarly references and sources cited throughout the presentation.
Outline
Approach toResearch
P.I.C.O. Summary
What is Reactive Arthritis?
Current Treatment Plan
Treatment-based Case Report
Remission
Remission-based Case Control Study
Questions for Future Research
Reactive Arthritis
‘Reiter’sSyndrome’ (classic triad)
1) Urethritis/Cervicitis
2) Conjunctivitis
3) Arthritis
Generally associated with HLA-B27 on
serology
Post-venereal type is particularly associated
with Chlamydia trachomatis infections
‘Can’t See, Can’t Pee, Can’t Climb a Tree.’
Chlamydia Trachomatis
• Mostprevalent sexually
transmitted bacterial pathogen
• May cause:
• Reactive arthritis (Reiter’s
syndrome)
• Follicular conjunctivitis
• Nongonococcal urethritis
(NGU)
• Pelvic inflammatory
disease (PID)
• 3 million new C. trachomatis
infections occur each year in the
United States
Source: Le, T. First aid 2014
Only 4% of these
cases lead to
inflammatory arthritis
13.
C. Trachomatis -Replication
Source: Carter, J.D. Int J Clin Rheumtol. 2011
14.
C. Trachomatis -Histology
Source: Carter, J.D. Int J Clin Rheumtol. 2011
Etanercept – CaseReport
Successful use of Etanercept
for the treatment of Reiter’s
syndrome: a case report and
review of the literature
(Edrees, A., 2011)
33 year old male with
Chlamydia-induced reactive
arthritis refractory to NSAIDs,
sulfasalazine, prednisone,
and methotrexate treatment
Source: Gc.kinesis.co.uk
17.
Etanercept – CaseReport
33 year old white male
Positive for Chlamydia
trachomatis
Treated with
azithromycin
3 weeks later: returns
with joint pain, itching
of both eyes, and
keratoderma
blennorrhagicum Source: Worldstemcells.com
Source: Wikipedia.org
18.
Etanercept – CaseReport
Two months without improvement
◦ Ibuprofen (800 mg t.i.d)
◦ Sulfasalazine (3000 mg q.d.)
◦ Methotrexate (15 mg once a week)
◦ Prednisone (20-60 mg q.d.)
Etanercept was started
(50 mg sc. once a week)
After two months, skin and joint pain improved.
Etanercept and methotrexate were continued for
12 months with resolution and no recurrence.
Source: Sweetclipart.com
19.
Conclusions
Etanercept isa TNF-alpha inhibitor
that may be used for patients that do not
respond to other treatment options
Although…
TNF-alpha has been shown to inhibit
growth of bacterial organisms, but
also causes an inflammatory response
In some cases, the use of TNF-alpha
inhibitors may lead to worsening of
symptoms
20.
Combination Therapy
Source: Lippincott,2006
• Treatment with
etanercept
together with
methotrexate
has been shown
to cause
remission in
patients with
reactive arthritis
21.
Remission
Definition: ‘a periodof time during a
serious illness when the patient's
health improves’
Approximately 15% of reactive
arthritis cases become chronic
and result in destructiveness of
the joints
Source: Merriam-Webster.com
22.
Remission – SystematicStudy
C. trachomatis is present and
metabolically active during the
remitting phase in synovial tissues
from patients with chronic Chlamydia-
induced reactive arthritis (Gerard,
H.C., Carter, J.D., Hudson, A.P., 2013)
4 patients in remission compared to 10
patients with active reactive arthritis…
23.
Remission – SystematicStudy
Synovial biopsies analyzed
using qPCR and RT-PCR
Bacterial load of patients in
remission was 20% of the load
in active patients
Heat shock protein 60
(hsp60), monocyte
chemotactic protein (MCP1),
RANTES (regulated on
activation, normal T cell
expressed and secreted)
mRNA levels were equal to or
higher in remitted patients
compared to active patients
Source: Aespecialists.com
Conclusion
Bacterial loadin synovium of patients
in remission are low; proinflammatory
proteins are equal to or higher than
patients with active reactive arthritis
Organism is present and metabolically
active in synovium during remission
Genetic patterns of patients in
remission are complex
27.
Future Research
Howexactly does
chlamydia replicate and
how can we create
therapeutic agents that
target every component
of these replication
patterns (transcription,
translation, etc.)?
How can we develop
nanotechnology that
introduces bactericidal
agents directly into target
sites in the synovium?
Source: Mynamesnotmommy.com
28.
Future Research
Whydo patients with reactive arthritis
relapse into active symptoms at low
bacterial loads?
What are the effects of
immunosuppressive drugs that
specifically target heat shock protein
60, monocyte chemotactic protein,
RANTES on patients with chronic
reactive arthritis?
Works Cited
1. Carter,J.D., Gerard, H.C., Whittum-Hudson, J.A. Hudson, A.P. Combination
antibiotics for the treatment of Chlamydia-induced reactive arthritis: is a cure in sight?
Int J Clin Rheumtol. 2011 June ; 6(3): 333–345. doi:10.2217/ijr.11.20.
2. Edrees, A. Successful use of Etanercept for the treatment of Reiter’s syndrome: a
case report and review of the literature. Rheumatol. Int. 2011. DOI 10.1003/600296-
011-2000-1.
3. Carter. J.D. Treating reactive arthritis: insights for the clinician. Ther. Adv.
Musculoskel. Dis. (2010) 45-54. DOI 10.1177/1759720X09357508.
4. Thank you [Online image]. (2014). Retrieved January 23, 2015 from
http://1.bp.blogspot.com/-zGehn2tMDsM/VITYRMs9JDI/AAAAAAAAM-A/j9v6UJoCM-
I/s1600/gold-heart-thank-you.png
5. Knee pain [Online image]. (2014). Retrieved January 23, 2015 from
http://sunshinecoastoliveoil.com/2013/11/06/the-beneficial-effect-of-evoo-on-arthritis/
6. http://guides.mclibrary.duke.edu/c.php?g=158201&p=1036068
7. Le, T., Bhushan, V., & Sochat, M. (2014). First aid for the usmle step 1. McGraw-Hill:
Chicago.
8. PCR machine [Online image]. (2014). Retrieved January 23, 2015 from
http://www.aespecialists.com/mold/wp-content/uploads/2012/04/Polymerase-Chain-
Reaction1.jpg
31.
Works Cited
9. Questionmark [Online image]. (2013). Retrieved January 23, 2015 from
http://www.mynamesnotmommy.com/wp-content/uploads/2013/05/question-mark.png
10. Syringe [Online image]. (2013). Retrieved January 23, 2015 from http://gc.kinesis.co.uk/wp-
content/uploads/002924.jpg
11. Checkmark [Online image]. (2014). Retrieved January 23, 2015 from http://sweetclipart.com/simple-
green-check-mark-1141
12. Types of studies [Online image]. (2015).Retrieved January 23, 2015 from
http://guides.mclibrary.duke.edu/c.php?g=158201&p=1036068
13. Arthritis [Online image]. (2014).Retrieved January 23, 2015 from
http://worldstemcells.com/psoriatic-arthritis.htm
14. Keratoderma blennorrhagicum [Online image]. (2014).Retrieved January 23, 2015 from
http://en.wikipedia.org/wiki/Keratoderma_blennorrhagicum#mediaviewer/File:Feet-
Reiters_syndrome.jpg
15. Gerard, H.C., Carter, J.D., Hudson, A.P. C. trachomatis is present and metabolically active during
the remitting phase in synovial tissues from patients with chronic Chlamydia-induced reactive
arthritis. Am J Med Sci. Jul 2013; 346(1): 10.1097/MAJ.0b013e3182648740.
16. Remission. (2015). http://www.merriam-webster.com/dictionary/remission
17. Howland, R.D. & Mycek, M.J. Edited by Harvey, R.A. & Champe, P.C. Lippincott’s illustrated
reviews: pharmacology. (2005). New Jersey: Lippincott Williams & Wilkins.
18. Vojvodic, M. & Young, A. (2014). Toronto Notes for Medical Students, Inc. Toronto: Type & Graphics
Inc.
19. PICO [Online image]. (2015).Retrieved January 26, 2015 from
http://www.jaypeejournals.com/eJournals/_eJournals%5C222%5C2012%5CJanuary-
March%5Cimages/2_img_0.jpg
Editor's Notes
#24 RT-PCR to check RNA expression, qPCR to check DNA expression